Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:06
07/06/20
07/06
09:06
07/06/20
09:06
UBER

Uber

$30.66 /

+0.24 (+0.79%)

, REGN

Regeneron

$620.76 /

+11.54 (+1.89%)

, BDX

Becton Dickinson

$245.09 /

+3.57 (+1.48%)

, SBH

Sally Beauty

$13.08 /

+0.17 (+1.32%)

, DTIL

Precision BioSciences

$8.44 /

+0.06 (+0.72%)

, SLCA

U.S. Silica

$3.36 /

+0.05 (+1.51%)

, SPOT

Spotify

$271.59 /

+12.63 (+4.88%)

, D

Dominion

$82.68 /

+0.32 (+0.39%)

, OBSV

ObsEva

$6.15 /

+0.17 (+2.84%)

Check out this morning's…

Open Full Text

ShowHide Related Items >><<
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

07/06/20 Wedbush
Uber's acquisition of Postmates 'a smart strategic move,' says Wedbush
07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 SunTrust
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
06/25/20 Deutsche Bank
Yandex interest in Uber's minority stake modest positive, says Deutsche Bank
REGN Regeneron
$620.76 /

+11.54 (+1.89%)

07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

07/02/20 Wells Fargo
Becton rallies after Wells says rapid COVID test may come very soon
07/02/20 Wells Fargo
Becton rapid antigen COVID test may be available very soon, says Wells Fargo
06/25/20 Raymond James
Becton Dickinson price target lowered to $265 from $290 at Raymond James
06/01/20
Fly Intel: Top five analyst initiations
SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform at Oppenheimer
06/04/20 Oppenheimer
Sally Beauty upgraded to Outperform from Perform at Oppenheimer
04/27/20 DA Davidson
Sally Beauty price target lowered to $10 from $14.50 at DA Davidson
04/20/20 Raymond James
Sally Beauty preliminary Q2 not as bad as feared, says Raymond James
DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

07/06/20 Evercore ISI
U.S. Silica upgraded to In Line from Underperform at Evercore ISI
03/19/20 Barclays
U.S. Silica upgraded to Equal Weight from Underweight at Barclays
03/11/20 Tudor Pickering
U.S. Silica downgraded to Hold from Buy at Tudor Pickering
03/09/20 Evercore ISI
U.S. Silica downgraded to Underperform from Outperform at Evercore ISI
SPOT Spotify
$271.59 /

+12.63 (+4.88%)

07/06/20 JPMorgan
Spotify price target raised to $305 from $185 at JPMorgan
07/06/20 Bernstein
Bernstein doubts Spotify will make money off podcasts, downgrades to sell
07/06/20 Bernstein
Spotify downgraded to Underperform from Market Perform at Bernstein
07/01/20 Wells Fargo
Spotify price target raised to $175 from $130 at Wells Fargo
D Dominion
$82.68 /

+0.32 (+0.39%)

07/06/20 JPMorgan
EQT could benefit from pipeline cancellation, says JPMorgan
07/06/20 JPMorgan
Dominion now positioned as 'best-in-class' utility, says JPMorgan
07/06/20 Guggenheim
Guggenheim 'loves' Dominion gas transmission sale, decision to scrap pipeline
06/09/20 Seaport Global
Dominion initiated with a Buy at Seaport Global
OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

03/24/20 Wedbush
ObsEva price target lowered to $34 from $40 at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 after pipeline update at Wedbush
03/05/20 Wedbush
ObsEva price target raised to $40 from $36 at Wedbush
12/19/19 H.C. Wainwright
ObsEva price target raised to $40 from $36 at H.C. Wainwright
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SLCA U.S. Silica
$3.36 /

+0.05 (+1.51%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

  • 27
    May
  • 21
    May
  • 11
    Feb
  • 07
    Nov
  • 06
    Nov
UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

D Dominion
$82.68 /

+0.32 (+0.39%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

SBH Sally Beauty
$13.08 /

+0.17 (+1.32%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

D Dominion
$82.68 /

+0.32 (+0.39%)

BDX Becton Dickinson
$245.09 /

+3.57 (+1.48%)

UBER Uber
$30.66 /

+0.24 (+0.79%)

SPOT Spotify
$271.59 /

+12.63 (+4.88%)

REGN Regeneron
$620.76 /

+11.54 (+1.89%)

OBSV ObsEva
$6.15 /

+0.17 (+2.84%)

D Dominion
$82.68 /

+0.32 (+0.39%)

Hot Stocks
Precision BioSciences regains rights to in vivo HBV program » 07:11
07/06/20
07/06
07:11
07/06/20
07:11
DTIL

Precision BioSciences

$8.44 /

+0.06 (+0.72%)

, GILD

Gilead

$76.31 /

+0.28 (+0.37%)

Precision BioSciences…

Precision BioSciences (DTIL) announced that the Company will regain full rights and all data it generated for the in vivo chronic hepatitis B virus, or HBV, program developed under its 2018 collaboration agreement with Gilead Sciences (GILD). Precision BioSciences said in a release, "Under the terms of the collaboration agreement, Precision BioSciences was primarily responsible for the development, formulation, and preclinical evaluation of the investigational nucleases for HBV; Gilead funded the research and development and was responsible for the clinical development and commercialization of potential therapies. Upon the collaboration's conclusion, effective September 4, 2020, Precision BioSciences will regain full clinical development and commercialization rights to the program. The Company does not anticipate any changes to its cash runway. As of March 31, 2020, Precision had cash and cash equivalents of $154.2 million, which is expected to sufficiently fund operations into the second half of 2021."

ShowHide Related Items >><<
GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
GILD Gilead
$76.31 /

+0.28 (+0.37%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

DTIL Precision BioSciences
$8.44 /

+0.06 (+0.72%)

GILD Gilead
$76.31 /

+0.28 (+0.37%)

Over a month ago
Conference/Events
Goldman Sachs to hold a virtual conference » 08:47
06/11/20
06/11
08:47
06/11/20
08:47
HUM

Humana

$392.51 /

+1.51 (+0.39%)

, DTIL

Precision BioSciences

$8.30 /

-0.31 (-3.60%)

, CHNG

Change Healthcare

$11.85 /

-0.37 (-3.03%)

, ALKS

Alkermes

$16.77 /

-0.51 (-2.95%)

, ALNY

Alnylam

$129.96 /

+0.09 (+0.07%)

, HCAT

Health Catalyst

$28.79 /

+0.1 (+0.35%)

, KLDO

Kaleido Biosciences

$7.44 /

-0.155 (-2.04%)

, ZEAL

Zealand Pharma

$39.08 /

+0.48 (+1.24%)

, GOSS

Gossamer Bio

$12.38 /

-0.23 (-1.82%)

, MRNA

Moderna

$59.88 /

+1.58 (+2.71%)

, ORTX

Orchard Therapeutics

$7.99 /

+0.23 (+2.96%)

, BMY

Bristol-Myers

$60.15 /

-0.75 (-1.23%)

, ADVM

Adverum Biotechnologies

$23.85 /

+0.44 (+1.88%)

, BCYC

Bicycle Therapeutics

$17.35 /

+0.15 (+0.87%)

, ESPR

Esperion

$46.64 /

-1.01 (-2.12%)

, PHAT

Phathom Pharmaceuticals

$50.33 /

-1.45 (-2.80%)

, INSP

Inspire Medical

$85.53 /

-3.11 (-3.51%)

, UBX

Unity Biotechnology

$8.88 /

+0.32 (+3.74%)

, PHG

Philips

$46.76 /

-0.39 (-0.83%)

, ATRA

Atara Biotherapeutics

$9.91 /

-0.455 (-4.39%)

41st Annual Global…

41st Annual Global Healthcare Virtual Conference will be held on June 9-11. Webcast Link

ShowHide Related Items >><<
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

06/05/20 Goldman Sachs
Humana initiated with a Buy at Goldman Sachs
06/01/20 Stephens
Molina Healthcare price target raised to $215 from $202 at Stephens
05/21/20 SunTrust
SunTrust raises price targets across select Healthcare Services names
05/04/20 Mizuho
Humana price target raised to $420 from $405 at Mizuho
DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

06/10/20 KeyBanc
Inovalon displaces Change Healthcare in Priority Health deal, says KeyBanc
06/09/20 Piper Sandler
Piper Sandler says buy Change Healthcare, sell Inovalon
04/13/20 SVB Leerink
Change Healthcare initiated with an Outperform at SVB Leerink
03/26/20 Cowen
Cowen sees three healthcare IT names poised for rebound
ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

04/30/20 H.C. Wainwright
Alkermes price target lowered to $23 from $25 at H.C. Wainwright
04/29/20 Piper Sandler
Alkermes price target lowered to $21 from $22 at Piper Sandler
04/29/20 Stifel
Alkermes price target lowered to $17 from $20 at Stifel
02/14/20 JPMorgan
JPMorgan downgrades Alkermes to Neutral into 'relatively quiet' 2020
ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

05/27/20 Piper Sandler
Piper bullish on post pandemic opportunities for Health Catalyst
05/15/20
Fly Intel: Top five analyst initiations
05/15/20 Guggenheim
Guggenheim sees Health Catalyst at attractive entry point, starts at Buy
05/15/20 Guggenheim
Health Catalyst initiated with a Buy at Guggenheim
KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

03/10/20 Morgan Stanley
Zealand Pharma EPS estimates cut at Morgan Stanley
11/19/19 Jefferies
Zealand Pharma downgraded to Hold from Buy at Jefferies
11/15/19 Needham
Zealand Pharma price target raised to $42 from $32 at Needham
10/15/19
Fly Intel: Top five analyst upgrades
GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

05/29/20 Piper Sandler
Piper says Gossamer's GB1275 well tolerated, early activity signs 'promising'
05/20/20 SVB Leerink
Gossamer Bio price target raised to $36 from $27 at SVB Leerink
04/22/20 Piper Sandler
Gossamer Bio initiated with an Overweight at Piper Sandler
02/27/20 Barclays
Gossamer Bio initiated with an Overweight at Barclays
MRNA Moderna
$59.88 /

+1.58 (+2.71%)

06/08/20 Barclays
Moderna initiated with an Overweight at Barclays
06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

05/22/20 JPMorgan
Orchard Therapeutics price target lowered to $17 from $26 at JPMorgan
09/17/19
Fly Intel: Top five analyst initiations
09/17/19
Guggenheim bullish on Orchard Therapeutics, initiates with a Buy
09/17/19 Guggenheim
Orchard Therapeutics initiated with a Buy at Guggenheim
BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

06/08/20 Bernstein
Gilead, AstraZeneca merger would make sense on economic basis, says Bernstein
06/02/20 Credit Suisse
Arena Pharmaceuticals price target raised to $87 from $77 at Credit Suisse
06/02/20 Cantor Fitzgerald
Arena Pharmaceuticals price target raised to $88 from $68 at Cantor Fitzgerald
06/02/20 Oppenheimer
Ayala Pharmaceuticals initiated with an Outperform at Oppenheimer
ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

05/29/20 Piper Sandler
Adverum Biotechnologies price target raised to $25 from $20 at Piper Sandler
05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
ESPR Esperion
$46.64 /

-1.01 (-2.12%)

05/07/20 Citi
Esperion price target raised to $56 from $46 at Citi
04/20/20 JMP Securities
JMP reiterates $191 price target on Esperion after Japan partnership
04/16/20 Northland
Esperion price target lowered to $42 from $60 at Northland
04/01/20
Fly Intel: Top five analyst initiations
PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

11/19/19 Evercore ISI
Phathom Pharmaceuticals initiated with an Outperform at Evercore ISI
11/19/19
Fly Intel: Top five analyst initiations
11/19/19 Needham
Phathom Pharmaceuticals initiated with a Buy at Needham
11/19/19 Jefferies
Phathom Pharmaceuticals initiated with a Buy at Jefferies
INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

05/26/20 Wells Fargo
Inspire Medical price target raised to $95 from $81 at Wells Fargo
05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Lake Street
Inspire Medical initiated with a Buy at Lake Street
05/06/20 Guggenheim
Inspire Medical price target raised to $90 from $80 at Guggenheim
UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

12/13/19
Unity Biotechnology management to meet with Mizuho
12/12/19 Cantor Fitzgerald
Unity Biotechnology assumed with an Overweight at Cantor Fitzgerald
PHG Philips
$46.76 /

-0.39 (-0.83%)

04/22/20 Morgan Stanley
Philips price target lowered to EUR 45 from EUR 50 at Morgan Stanley
04/21/20 JPMorgan
Philips price target raised to EUR 36.80 from EUR 33.90 at JPMorgan
04/07/20 JPMorgan
Philips price target lowered to EUR 33.90 from EUR 43.10 at JPMorgan
03/24/20 DZ Bank
Philips upgraded to Buy from Hold at DZ Bank
ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

05/22/20 Mizuho
Atara multiple sclerosis data looks 'awesome' at first glance, says Mizuho
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy on valuation at Citi
04/23/20 Citi
Atara Biotherapeutics upgraded to Buy from Neutral at Citi
11/08/19 JPMorgan
Atara Biotherapeutics downgraded to on lack of catalysts at JPMorgan
ZEAL Zealand Pharma
$39.08 /

+0.48 (+1.24%)

UBX Unity Biotechnology
$8.88 /

+0.32 (+3.74%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ATRA Atara Biotherapeutics
$9.91 /

-0.455 (-4.39%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

ALNY Alnylam
$129.96 /

+0.09 (+0.07%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

PHG Philips
$46.76 /

-0.39 (-0.83%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

KLDO Kaleido Biosciences
$7.44 /

-0.155 (-2.04%)

INSP Inspire Medical
$85.53 /

-3.11 (-3.51%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

HCAT Health Catalyst
$28.79 /

+0.1 (+0.35%)

GOSS Gossamer Bio
$12.38 /

-0.23 (-1.82%)

DTIL Precision BioSciences
$8.30 /

-0.31 (-3.60%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

BCYC Bicycle Therapeutics
$17.35 /

+0.15 (+0.87%)

ALKS Alkermes
$16.77 /

-0.51 (-2.95%)

ADVM Adverum Biotechnologies
$23.85 /

+0.44 (+1.88%)

PHAT Phathom Pharmaceuticals
$50.33 /

-1.45 (-2.80%)

ORTX Orchard Therapeutics
$7.99 /

+0.23 (+2.96%)

MRNA Moderna
$59.88 /

+1.58 (+2.71%)

HUM Humana
$392.51 /

+1.51 (+0.39%)

ESPR Esperion
$46.64 /

-1.01 (-2.12%)

CHNG Change Healthcare
$11.85 /

-0.37 (-3.03%)

BMY Bristol-Myers
$60.15 /

-0.75 (-1.23%)

Hot Stocks
Precision BioSciences doses first patient in Phase 1/2a trial of PBCAR269A » 07:04
06/08/20
06/08
07:04
06/08/20
07:04
DTIL

Precision BioSciences

$7.13 /

+ (+0.00%)

Precision BioSciences…

Precision BioSciences announced that the first patient has been dosed in a Phase 1/2a clinical trial of PBCAR269A, its third allogeneic chimeric antigen receptor T cell therapy candidate. Wholly-owned by Precision, PBCAR269A targets the B-cell maturation antigen and is being evaluated for the treatment of relapsed/refractory multiple myeloma. In preclinical disease models, PBCAR269A demonstrated potent in vivo clearance of BCMA+ tumor cells and overall tumor volume reduction, with no evidence of graft-versus-host disease. Clinical trial material for this study is generated at the Company's in-house Manufacturing Center for Advanced Therapeutics in Durham, North Carolina. PBCAR269A has received Orphan Drug Designation from the FDA for the treatment of multiple myeloma.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.13 /

+ (+0.00%)

DTIL Precision BioSciences
$7.13 /

+ (+0.00%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
DTIL Precision BioSciences
$7.13 /

+ (+0.00%)

DTIL Precision BioSciences
$7.13 /

+ (+0.00%)

Syndicate
Precision BioSciences files $200M mixed securities shelf  17:33
06/01/20
06/01
17:33
06/01/20
17:33
DTIL

Precision BioSciences

$7.09 /

+0.11 (+1.58%)

 
ShowHide Related Items >><<
DTIL Precision BioSciences
$7.09 /

+0.11 (+1.58%)

DTIL Precision BioSciences
$7.09 /

+0.11 (+1.58%)

05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
DTIL Precision BioSciences
$7.09 /

+0.11 (+1.58%)

DTIL Precision BioSciences
$7.09 /

+0.11 (+1.58%)

DTIL Precision BioSciences
$7.09 /

+0.11 (+1.58%)

Recommendations
Precision BioSciences could have 'significant upside,' says H.C. Wainwright » 07:12
05/18/20
05/18
07:12
05/18/20
07:12
DTIL

Precision BioSciences

$7.80 /

+0.58 (+8.03%)

, ALLO

Allogene Therapeutics

$44.87 /

+2.78 (+6.60%)

At an enterprise value of…

At an enterprise value of $250M versus $5B for Allogene Therapeutics (ALLO), Precision BioSciences (DTIL) could have "significant upside" if the upcoming data exceed the 70% overall response rate threshold, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. The analyst believes Precision's current valuation provides a "compelling" entry point and keeps a Buy rating on the shares with a $19 price target.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.80 /

+0.58 (+8.03%)

ALLO Allogene Therapeutics
$44.87 /

+2.78 (+6.60%)

DTIL Precision BioSciences
$7.80 /

+0.58 (+8.03%)

04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
02/25/20 William Blair
Precision BioSciences initiated with an Outperform at William Blair
ALLO Allogene Therapeutics
$44.87 /

+2.78 (+6.60%)

05/15/20 Guggenheim
Guggenheim upgrades Allogene to Buy with $50 target after ASCO upside surprise
05/15/20 Guggenheim
Allogene Therapeutics upgraded to Buy from Neutral at Guggenheim
05/14/20 Oppenheimer
Allogene Therapeutics price target raised to $50 from $44 at Oppenheimer
05/14/20 Jefferies
Jefferies raises price target on 'ASCO winner' Allogene Therapeutics to $45
DTIL Precision BioSciences
$7.80 /

+0.58 (+8.03%)

ALLO Allogene Therapeutics
$44.87 /

+2.78 (+6.60%)

DTIL Precision BioSciences
$7.80 /

+0.58 (+8.03%)

ALLO Allogene Therapeutics
$44.87 /

+2.78 (+6.60%)

DTIL Precision BioSciences
$7.80 /

+0.58 (+8.03%)

Hot Stocks
Precision BioSciences has not experienced material delays to trials » 07:07
05/15/20
05/15
07:07
05/15/20
07:07
DTIL

Precision BioSciences

$7.22 /

+0.65 (+9.89%)

In April 2020, Precision…

In April 2020, Precision provided an update regarding its clinical trials and business operations amid the COVID-19 pandemic. This includes steps taken in line with guidance from public health officials to protect the health and safety of its employees and to ensure continuity of its clinical trials. Precision's work-from-home policy and restriction of on-site activities to certain manufacturing functions and limited laboratory and support activities remain in effect. To date, Precision has not experienced material delays to its planned or ongoing clinical trials.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
02/25/20 William Blair
Precision BioSciences initiated with an Outperform at William Blair
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

Hot Stocks
Precision BioSciences to select clinical candidate for PH1 program in 2020 » 07:06
05/15/20
05/15
07:06
05/15/20
07:06
DTIL

Precision BioSciences

$7.22 /

+0.65 (+9.89%)

In January 2020,…

In January 2020, Precision announced that its first wholly-owned in vivo gene correction program will apply its ARCUS genome editing technology to knock out the HAO1 gene as a potential one-time treatment for primary hyperoxaluria type 1, a rare genetic disease. In 2020, Precision expects to select a clinical candidate for this program to advance into human trials.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
02/25/20 William Blair
Precision BioSciences initiated with an Outperform at William Blair
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

Hot Stocks
Precision BioSciences to begin dosing in Phase 1/2a trial of PBCAR269A in 2020 » 07:06
05/15/20
05/15
07:06
05/15/20
07:06
DTIL

Precision BioSciences

$7.22 /

+0.65 (+9.89%)

PBCAR269A is a…

PBCAR269A is a wholly-owned investigational allogeneic CAR T candidate targeting B-cell maturation antigen for the treatment of R/R multiple myeloma, for which Precision has also received ODD. In January 2020, the FDA cleared Precision's Investigational New Drug application for PBCAR269A, and the Company expects to begin dosing patients in a Phase 1/2a clinical trial in 2020.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
02/25/20 William Blair
Precision BioSciences initiated with an Outperform at William Blair
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

Hot Stocks
Precision BioSciences expects data from PBCAR0191 trial in 2020 » 07:05
05/15/20
05/15
07:05
05/15/20
07:05
DTIL

Precision BioSciences

$7.22 /

+0.65 (+9.89%)

PBCAR0191 is an…

PBCAR0191 is an investigational allogeneic CAR T candidate targeting CD19, currently being evaluated in a Phase 1/2a study in relapsed or refractory non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia. The NHL cohort will include patients with mantle cell lymphoma, an aggressive subtype of NHL, for which Precision has received Orphan Drug Designation from the U.S. Food and Drug Administration. In the first quarter of 2020, after discussion with the FDA, Precision implemented an amendment to the PBCAR0191 trial protocol designed to further optimize clinical activity. The amended trial design is intended to specifically address key clinical questions, which include assessing the impact of higher total doses of cells on clinical activity and/or the impact of modified lymphodepletion on the ability to achieve durable clinical benefit with associated CAR T cell expansion and persistence. The PBCAR0191 clinical trial continues to progress, and no dose limiting toxicities or serious adverse events have been observed to date. Precision expects to present updated interim clinical data from both the NHL and B-ALL cohorts of this trial during 2020. PBCAR0191 is being developed in collaboration with Servier, an international pharmaceutical company.

ShowHide Related Items >><<
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
03/04/20 Stifel
Precision BioSciences initiated with a Buy at Stifel
02/25/20 William Blair
Precision BioSciences initiated with an Outperform at William Blair
DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

DTIL Precision BioSciences
$7.22 /

+0.65 (+9.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.